NCT02423057
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT02423057